COMMUNIQUÉS West-GlobeNewswire

Kraig Biocraft Laboratories Reports Signing Landmark Agreements in South East Asia

29/04/2024 - 13:05

ANN ARBOR, Mich., April 29, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company"), announces today that it has signed key agreements with the Lam Dong Agro-Forestry Research Experiment [...]

EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases

29/04/2024 - 13:00

Long-term data and subgroup analyses from pivotal EYLEA HD clinical program continue to demonstrate durable efficacy and consistent safety in patients with wet age-related macular degeneration and certain diabetic eye [...]

George Medicines Appoints Mark Mallon as Chief Executive Officer and Board Director

29/04/2024 - 13:00

George Medicines Appoints Mark Mallon as Chief Executive Officer and Board Director London, UK 29 April 2024 – George Medicines, a late-stage, biopharmaceutical company addressing significant unmet need in the treatment [...]

Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement

29/04/2024 - 13:00

Boston (April 29, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that on [...]

Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024

29/04/2024 - 13:00

BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious [...]

FibroGen to Report First Quarter 2024 Financial Results

29/04/2024 - 13:00

SAN FRANCISCO, April 29, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter 2024 financial results on Monday, May 6 after the market close. FibroGen will also conduct a conference call on [...]

Breckenridge Brewery Introduces New West Coast Style IPA ‘Ridge Runner’

29/04/2024 - 13:00

The Perfect Beer for Toasting The Trail Less Traveled LITTLETON, Colo., April 29, 2024 (GLOBE NEWSWIRE) -- Breckenridge Brewery (“Breck Brew”) a subsidiary of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), is [...]

Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer

29/04/2024 - 13:00

CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc . (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment of Mary Kay [...]

Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)

29/04/2024 - 13:00

First-Ever Open IND for Prime Editing Technology PM359 is Prime Medicine’s Ex Vivo Product Candidate Designed to Correct a Prevalent Disease-Causing Mutation of CGD Initial Data Expected in 2025 CAMBRIDGE, Mass., April [...]

Gritstone bio Announces Appointment of Stephen Webster to its Board of Directors

29/04/2024 - 13:00

EMERYVILLE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced the appointment of [...]

Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024

29/04/2024 - 13:00

THE WOODLANDS, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its first quarter 2024 financial results on Thursday, May 2, 2024 after the markets close. Management [...]

Transactions in Connection with Share Buy-back Program Genmab

29/04/2024 - 10:24

Company Announcement COPENHAGEN, Denmark; April 29, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. [...]

ENA Respiratory Announces FDA IND Clearance for its Prophylactic Intranasal INNA-051 - a First-in-Class Antiviral Innate Immunomodulator

29/04/2024 - 10:00

MELBOURNE, Australia, April 29, 2024 (GLOBE NEWSWIRE) -- ENA Respiratory , a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory [...]

Calibre Scientific Acquires Camlab Limited, a UK Provider of Scientific Equipment, Chemicals, Consumables and Other Laboratory Supplies

29/04/2024 - 10:00

LOS ANGELES, April 29, 2024 (GLOBE NEWSWIRE) -- Calibre Scientific is pleased to announce the acquisition of Camlab Limited (“Camlab” or the “Company”), a UK-based supplier of scientific equipment, chemicals, [...]

Burning Rock Publishes 2023 Annual Report on Form 20-F

29/04/2024 - 09:30

GUANGZHOU, China, April 29, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing [...]

Evox Therapeutics Names Co-Founder Dr. Per Lundin as Chief Executive Officer

29/04/2024 - 08:00

OXFORD, United Kingdom, April 29, 2024 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, announces that Dr. Per Lundin, Co-Founder and Chief Business Officer, [...]

Olansi Healthcare Co., Ltd Redefines home water solutions with its best countertop water purifiers, hot and cold RO water purifiers and hot/cold water dispensers

29/04/2024 - 07:00

Guangzhou, China, April 29, 2024 (GLOBE NEWSWIRE) -- In response to the increasing demand for safe and convenient water solutions in homes worldwide, Olansi Healthcare Co., Ltd announces the launch of its latest lineup [...]

Addex Provides Update on ADX71149 Phase 2 Epilepsy Study

29/04/2024 - 07:00

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small [...]

Mithra updates on offers received in the context of its monetization process and on its Annual Report 2023

29/04/2024 - 07:00

Mithra has received binding offers for selected assets, including Estetra SRL, as part of its monetization process. As it stands, the aggregate amount of these offers is insufficient to ensure full repayment of all [...]